Company intelligence / Profile preview

Shanghai Mianyi Biotechnology

Shanghai, Shanghai Shi, China

Ownership: Private
Development stage: Other

Overview

Shanghai Mianyi Biotechnology specializes in adeno-associated viral (AAV) vector-based gene therapies, with their lead candidate BBM-H803 in Phase 1/2 clinical trials targeting Hemophilia A and BBM-D101 in early clinical trials for Duchenne muscular dystrophy. Initial clinical trial data for BBM-H803 shows ongoing recruitment and active evaluation of safety and efficacy[1][7].

Therapeutic areas: HematologyRare DiseasesRheumatology
Modalities: Gene therapyAAV based gene therapy
Industry: Biotech

Partnerships

Shanghai Jiao Tong University School of Medicine (clinical trial collaboration for BBM-D101)[7]

Beyond the preview

Go deeper on Shanghai Mianyi Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Mianyi Biotechnology.

Explore the full profile